News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

Oct 19, 2006
Porton Down, UK, 19 October 2006: GW Pharmaceuticals plc (AIM: GWP) (“GW” or “the Company”) and Bayer HealthCare, Pharmaceuticals Division - Canada (“Bayer”) announce that GW has submitted a regulat
Oct 03, 2006
Porton Down, UK, 3 October 2006 – GW Pharmaceuticals plc (AIM: GWP) announces today that results from two Phase III studies of Sativex ® were presented at Europe's leading multiple sclerosis (MS) co
Sep 05, 2006
Porton Down, UK, 5 September 2006 - GW Pharmaceuticals plc (AIM: GWP) (“GW” or “the Company”) today announces that it has filed a regulatory submission in selected European countries for Sativex®, i
Aug 09, 2006
Porton Down, UK, 9 August 2006 - GW Pharmaceuticals plc (AIM: GWP) announces the start of a second pivotal Phase III trial in people with multiple sclerosis (MS) suffering from central neuropathic p
Jun 20, 2006
Porton Down, UK, 20 June 2006: GW Pharmaceuticals plc (AIM: GWP), the developer and manufacturer of a range of new medicines based on cannabis and other controlled drugs, announces its interim resul
May 16, 2006
GW Pharmaceuticals plc (AIM: GWP) is today pleased to announce the appointment of Investec Bank (UK) Limited as Nominated Adviser and Broker to the Company with immediate effect.
Mar 17, 2006
Porton Down, UK, 17 March 2006 - GW Pharmaceuticals plc (AIM: GWP) today announces preliminary results from a Phase III study of Sativex® in the relief of spasticity in people with Multiple Sclerosi
Feb 10, 2006
GW Pharmaceuticals today announces the appointment of Mr David Morrison as a non-executive director with immediate effect.
Jan 19, 2006
GW Pharmaceuticals plc, the company which develops and manufactures a range of new medicines based on cannabis and other controlled drugs, announces its preliminary results for the year ended 30 September 2005.
Jan 04, 2006
GW Pharmaceuticals plc (AiM:GWP) today announces that it has signed an agreement with a United States-based institutional investor to raise $15 million (£8.6 million) before expenses through a placing for cash of 6,

Pages